CHMP recommends approval of bosutinib (Bosulif®) for CML

Source: European Medicines Agency Area: News The Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of a conditional marketing authorisation for the orphan medicine bosutinib (Bosulif®) for the treatment of adults with Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) (TKIs) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. Bosutinib is a protein kinase inhibitor that acts by inhibiting the abnormal Bcr-Abl kinase that promotes CML.   The positive opinion was based on data from an open-label, single-arm Phase 1/2 study which included over 500 patients with Ph+ CML, with separate cohorts for chronic, accelerated and blast phase disease previously treated with one or more prior TKIs. The summary of opinion notes that the benefits associated with bosutinib are its haematological or cytogenetic response rates in this population (no details reported). On the ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news

Related Links:

Authors: Miyoshi I, Mori M, Yamasaki I, Daibata M PMID: 32224562 [PubMed - in process]
Source: Journal of Clinical and Experimental Hematopathology : JCEH - Category: Hematology Tags: J Clin Exp Hematop Source Type: research
A 34-year-old man with chronic myelogenous leukemia status post allogeneic hematopoietic stem cell transplant (HSCT) on tacrolimus for graft-vs-host disease prophylaxis, presented with a 1-week history of fevers and severe headaches. Brain magnetic resonance imaging (MRI) demonstrated numerous small focal lesions in the left basal ganglia and left temporal lobe with a ring pattern, as well  as a large lesion in the left occipital lobe with mild leptomeningeal enhancement (Figure 1). Cerebrospinal fluid (CSF) analysis revealed lymphocytic pleocytosis, and Toxoplasma gondii was detected by polymerase chain reaction (PCR).
Source: Mayo Clinic Proceedings - Category: Internal Medicine Authors: Tags: Medical image Source Type: research
sco Salvo Tyrosine kinase inhibitors (TKIs), the treatment of choice for chronic myeloid leukemia (CML), can be associated to cardiovascular (CV) adverse events (AEs). A case/non-case study was performed using AE reports registered in the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database to compare the risk of CV event reports related to TKIs indicated in the management of chronic myeloid leukemia (CML). Disproportionality of CV event-related TKIs was computed using the Reporting Odds Ratio (ROR) as a measure of potential risk increase. Nilotinib accounts for more than half of reported ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
AbstractBackgroundSALL4 is a zinc finger transcription factor that exerts its physiological role during embryo-fetal development. Analyses of SALL4 expression have shown its oncogenic role in precursor B-cell lymphoblastic lymphoma, acute and chronic myeloid leukemia, gastrointestinal, breast, and lung cancers. The aim of this study was to determine the immunohistochemical profile of SALL4 in pediatric yolk sac tumors (YSTs).Methods and resultsImmunohistochemistry detection of SALL4 was performed in 22 cases of pediatric YSTs and 10 mature teratomas. The percentage of tumor cells stained was scored as 0, 1+  (1&ndas...
Source: Pediatric Surgery International - Category: Surgery Source Type: research
We present the first reported case of GA in a patient with essential thrombocythemia (ET). Future work investigating the shared pathophysiology of GA ‐associated CML and ET may improve our understanding of GA pathophysiology and treatment. AbstractThe only myeloproliferative neoplasm associated with generalized granuloma annulare (GA) is chronic myelogenous leukemia (CML). We present the first reported case of GA in a patient with essential thrombocythemia (ET). Future work investigating the shared pathophysiology of GA ‐associated CML and ET may improve our understanding of GA pathophysiology and treatment.
Source: Clinical Case Reports - Category: General Medicine Authors: Tags: CASE REPORT Source Type: research
Authors: Fujita M, Kamachi K, Yokoo M, Kidoguchi K, Kusaba K, Kizuka-Sano H, Yamaguchi K, Nishioka A, Yoshimura M, Kubota Y, Ando T, Kojima K, Kimura S Abstract Patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) are often asymptomatic and thus can remain undiagnosed until they become symptomatic due to progression to the accelerated phase (AP) or transformation to acute leukemia (leukemic transformation; LT). We herein report the case of a previously healthy 38-year-old man who had hyperleukocytosis with dysplastic myeloid precursor cells and severe disseminated intravascular coagulation. ...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
PMID: 32200529 [PubMed - as supplied by publisher]
Source: International Journal of Hematology - Category: Hematology Authors: Tags: Int J Hematol Source Type: research
Publication date: Available online 17 March 2020Source: Cancer GeneticsAuthor(s): Jaime L. Lopes, Matthew Webley, Beth A. Pitel, Kathryn E. Pearce, James B. Smadbeck, Sarah H. Johnson, George Vasmatzis, William R. Sukov, Patricia T. Greipp, Nicole L. Hoppman, Rhett P. Ketterling, Linda B. Baughn, Laura Finn, Jess F. Peterson
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research
(Duke-NUS Medical School) Scientists and clinicians from Duke-NUS Medical School, the Agency for Science, Technology and Research's (A*STAR's) Genome Institute of Singapore (GIS), and the Singapore General Hospital (SGH), have devised a novel drug combination that could treat a particularly deadly form of leukaemia, known as blast crisis (BC) chronic myeloid leukaemia (CML). The team has also developed strategies that may identify patients with early stage or chronic phase (CP) CML who are at increased risk of developing BC, and potentially preventing disease progression.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
CONCLUSION: The 3-(acridin-9-ylmethyl)-5-((10-chloroanthracen-9-yl)methylene)thiazolidine-2,4-dione (LPSF/AA-62) presented the most promising results, showing anti-tumor activity in 5 of the 6 cell types tested, especially inhibiting the formation of colonies of prostate tumor cells (DU-145). PMID: 32189590 [PubMed - as supplied by publisher]
Source: Combinatorial Chemistry and High Throughput Screening - Category: Chemistry Authors: Tags: Comb Chem High Throughput Screen Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Drugs & Pharmacology | European Medicines Agency (EMA) | Gleevec | Leukemia | Marketing | Nilotinib | Study | Tasigna